We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Show more
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0178 | 2.36639191704 | 0.7522 | 0.871 | 0.7522 | 191300 | 0.81507683 | CS |
4 | -0.25 | -24.5098039216 | 1.02 | 1.09 | 0.7266 | 225890 | 0.84383095 | CS |
12 | 0.135 | 21.2598425197 | 0.635 | 1.2 | 0.62 | 417279 | 0.89941084 | CS |
26 | 0.0249 | 3.34183331096 | 0.7451 | 1.2 | 0.5438 | 350243 | 0.79168774 | CS |
52 | -0.47 | -37.9032258065 | 1.24 | 1.34 | 0.5388 | 245993 | 0.86384001 | CS |
156 | -26.34 | -97.1597196606 | 27.11 | 34.31 | 0.5388 | 257786 | 4.44408456 | CS |
260 | -13.97 | -94.776119403 | 14.74 | 37.5099 | 0.5388 | 237596 | 6.01294555 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions